Welcome to our dedicated page for POSITRON news (Ticker: POSC), a resource for investors and traders seeking the latest updates and insights on POSITRON stock.
Positron Corporation is a nuclear medicine healthcare company specializing in the field of cardiac Positron Emission Tomography (PET) imaging. With over 30 years of focus on cardiac PET, Positron aims to make this superior modality more accessible to clinicians and patients worldwide. Their Attrius® system, optimized for MPI, offers cutting-edge technology and accurate diagnostic capabilities in cardiac imaging.
Positron (OTC: POSC) has partnered with Upbeat Cardiology Solutions to expand its PET-CT imaging systems and services. The collaboration focuses on providing cardiology practices with NeuSight PET-CT 64 Slice scanner technology and turnkey solutions. Upbeat Cardiology Solutions will offer comprehensive services including equipment acquisition, installation, staff training, and isotope supply. The partnership aims to make cardiac PET-CT imaging more accessible to private practices, offering superior diagnostic accuracy, reduced scan times, and higher reimbursement rates compared to traditional SPECT imaging.
Positron (OTC: POSC) has launched its Prime Rental Program, offering PET-CT systems with comprehensive services for a single monthly fee. This program aims to make advanced imaging technology accessible to practices of all sizes by eliminating upfront capital expenditure. The package includes:
- Positron's PET-CT 64 Slice scanner
- Clinical & technical support
- Technician training services
- Preventative maintenance
Key benefits include flexible financing, comprehensive services, future upgrades, and potential tax advantages. The NeuSight PET-CT, designed for both cardiology and oncology applications, features a 72cm gantry, high-sensitivity acquisition technology, and the smallest footprint in its class. This initiative aims to stimulate demand for PET-CT technology and accelerate its adoption in healthcare practices.
Positron (OTC: POSC) has announced the sale of its NeuSight PET-CT 64 slice scanner to a leading cardiovascular services provider. The NeuSight PET-CT is designed to revolutionize cardiac PET imaging, offering advanced technology at a competitive price. Key features include:
- 500 installations worldwide
- 72cm gantry for patient comfort
- High-sensitivity acquisition technology for minimal radiation exposure
- Smallest footprint and lightest weight in its class
- Suitable for cardiology and oncology studies
- Superior data acquisition and improved scanning speed and accuracy
Positron's President, Adel Abdullah, expressed enthusiasm about the sale and the positive market response since the scanner's introduction in late July. The company aims to continue offering this technology to practices and hospitals in the future.
Positron (OTC: POSC) has introduced its new NeuSight PET-CT 3D 64 slice scanner for the US and North American markets. This advanced imaging system sets a new standard in diagnostic precision, patient comfort, and operational efficiency for nuclear cardiology practices and hospitals. The scanner offers superior image clarity and resolution, essential for accurate cardiac diagnostics, and is designed for both cardiology and oncology clinical studies.
Key features include a spacious 72cm gantry, high-sensitivity acquisition technology, and the smallest footprint and lightest weight of any PET-CT 64 slice system in the industry. Positron has exclusive rights for North American distribution through a partnership with Neusoft Medical Systems. The company aims to meet increased demand in nuclear cardiology driven by technological advancements and favorable reimbursement environment.
Positron (POSC) announced the order of five NeuSight PET-CT 64 slice scanners from Neusoft Medical Systems’ subsidiary, Shenyang Intelligent Neuclear Medical Technology Co. This move follows the recent introduction of the NeuSight PET-CT system to the US market. Neusoft Medical Systems, a global leader in medical device development, has sold approximately 500 NeuSight systems internationally and possesses ample production capacity to meet increased demand prompted by this expansion. Positron aims to deliver the systems within 12 weeks, aligning with the timeframe needed for practices to secure radiopharmaceutical supply agreements. President Adel Abdullah emphasized that this order is the initial phase of Positron's strategy to address customer needs and support the advancement of cardiac PET-CT.
Positron (OTC: POSC) has announced the sale of its Attrius® PET System to a cardiovascular practice in Michigan. The installation is scheduled for Q4 2024. The Attrius PET scanner excels in nuclear cardiology, offering high-resolution images and precise blood flow analysis. The new customer will benefit from Positron's Lease to Own Program, which requires zero upfront capital expenditure and includes the complete Attrius PET System and comprehensive clinical and technical services for a monthly fee. Positron's President, Adel Abdullah, emphasized the system's ability to enhance cardiac diagnostics and its cost-effective operational model for nuclear imaging practices.
Positron (OTC: POSC), a leading molecular imaging medical device company, has joined the Cardiac PET Industry Coalition (CPIC). The coalition includes founding members such as Bracco Diagnostics, CDL Nuclear Technologies, and Siemens Healthcare, united to promote federal policies enhancing healthcare outcomes for cardiovascular disease patients. CPIC aims to improve access to cardiac PET diagnostics across the U.S., advocate for fair reimbursement policies, and educate healthcare providers and policymakers on the benefits of cardiac PET. Positron President Adel Abdullah emphasized the company's commitment to the coalition's goals and its role in advancing PET technology.
Positron (OTC: POSC) has secured exclusive North American rights to sell and distribute the NeuSight PET-CT 64 slice scanner through an agreement with Shenyang Intelligent Nuclear Medical Technology Co., a subsidiary of Neusoft Medical Systems. This award-winning scanner has FDA clearance for the US market and will be introduced in July 2024 for nuclear cardiac imaging. NeuSight PET-CT 64 offers advanced imaging for heart, tumor, and brain studies, combining anatomical and functional imaging with improved speed and accuracy. Positron aims to meet the increasing demand in the US, Canada, and Mexico, leveraging the system’s international success, with around 500 units sold globally.
Positron (OTC: POSC) has entered an agreement to acquire the FDA 510(k) clearance for the NeuSight PET-CT from Neusoft Medical Systems' subsidiary. This acquisition enables Positron to immediately market and sell the NeuSight PET-CT 64 slice imaging system and facilitates future FDA clearances for their Affinity PET-CT 4D 64 slice system. Adel Abdullah, President of Positron, emphasized that this milestone will significantly enhance their product line, which is vital for both oncology and nuclear cardiology. Positron aims to offer advanced PET-CT technology to healthcare practices, supported by Neusoft's extensive R&D expertise.
FAQ
What is the current stock price of POSITRON (POSC)?
What is the market cap of POSITRON (POSC)?
What is Positron Corporation known for?
What is the significance of cardiac PET imaging?
What is the Attrius® system by Positron Corporation?
How does Positron Corporation aim to make cardiac PET more accessible?
How long has Positron Corporation been supporting cardiac PET?
What are the benefits of using the Attrius® system for cardiac imaging?
Where can I find more information about Positron Corporation?
Who do I contact for Investor Relations at Positron Corporation?
What type of imaging technology does Positron Corporation specialize in?
How does the Attrius® system compare to other imaging modalities?
What makes Positron Corporation a leader in cardiac PET imaging?
